- Home
- MPB vs PHAT Comparison
MPB vs PHAT Comparison
Compare MPB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PHAT
- Stock Information
- Founded
- MPB 1868
- PHAT 2018
- Country
- MPB United States
- PHAT United States
- Employees
- MPB N/A
- PHAT N/A
- Industry
- MPB Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PHAT Health Care
- Exchange
- MPB Nasdaq
- PHAT Nasdaq
- Market Cap
- MPB 634.9M
- PHAT 727.5M
- IPO Year
- MPB N/A
- PHAT 2019
- Fundamental
- Price
- MPB $30.22
- PHAT $8.91
- Analyst Decision
- MPB Buy
- PHAT Strong Buy
- Analyst Count
- MPB 2
- PHAT 5
- Target Price
- MPB $36.00
- PHAT $16.40
- AVG Volume (30 Days)
- MPB 99.3K
- PHAT 5.0M
- Earning Date
- MPB 07-23-2025
- PHAT 08-07-2025
- Dividend Yield
- MPB 2.65%
- PHAT N/A
- EPS Growth
- MPB 23.94
- PHAT N/A
- EPS
- MPB 2.88
- PHAT N/A
- Revenue
- MPB $181,865,000.00
- PHAT $81,859,000.00
- Revenue This Year
- MPB $24.31
- PHAT $195.45
- Revenue Next Year
- MPB $13.74
- PHAT $106.76
- P/E Ratio
- MPB $10.50
- PHAT N/A
- Revenue Growth
- MPB 9.21
- PHAT 3055.70
- 52 Week Low
- MPB $21.11
- PHAT $2.21
- 52 Week High
- MPB $33.87
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- MPB 75.03
- PHAT 53.97
- Support Level
- MPB $28.02
- PHAT $8.72
- Resistance Level
- MPB $28.48
- PHAT $10.13
- Average True Range (ATR)
- MPB 0.60
- PHAT 0.81
- MACD
- MPB 0.33
- PHAT -0.33
- Stochastic Oscillator
- MPB 100.00
- PHAT 3.96
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.